Drugs / 4SCAR-Her2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04430595 | Jun 2026 → Dec 2029 expected | breast cancer | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4SCAR-Her2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04430595 ↗ |
| Modality | Cell therapy | “Multiple 4th generation CAR-T cells targeting Her2, GD2, and CD44v6 surface antigen” NCT04430595 ↗ |
| Route | Other | “Infusion of 4SCAR-GD2, -Her2 and -CD44v6 CAR-T cells” NCT04430595 ↗ |